Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
BioCryst Pharmaceuticals |
---|---|
Information provided by: | BioCryst Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT00486980 |
This is a multinational, randomized, double-blind study comparing the efficacy and safety of two single dose regimens of peramivir administered intramuscularly versus placebo in adults with uncomplicated acute influenza.
Condition | Intervention | Phase |
---|---|---|
Influenza |
Drug: Peramivir 150mg Drug: Peramivir 300mg |
Phase III |
Study Type: | Interventional |
Study Design: | Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAMUSCULAR PERAMIVIR IN SUBJECTS WITH UNCOMPLICATED ACUTE INFLUENZA |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | BCX1812-312 |
Study First Received: | June 14, 2007 |
Last Updated: | January 28, 2008 |
ClinicalTrials.gov Identifier: | NCT00486980 |
Health Authority: | TBD |
influenza |
Virus Diseases Respiratory Tract Diseases Respiratory Tract Infections Influenza, Human Orthomyxoviridae Infections |
RNA Virus Infections |